Month: February 2016

24 Feb 2016


The first paediatric antimalarial that has been granted a positive scientific opinion from the European Medicines Agency (EMA), under Article 58 is Pyramax® Granules. Pyramax® Granules is a fixed-dose artemisinin combination therapy (ACT) of pyronaridine and artesunate. With this opinion, the registration and use of Pyramax® Granules on children in malaria stricken areas will be supported.

Given the fact that a child would need to complete the full dose in order to attain a cure, it is appropriate that the granule formulation is taste-masked, suspends in only 2 teaspoons of liquid and only requires a once daily dose for 3 days, making treatment compliance simple for sick children.

According to Medicines for Malaria Venture’s CEO, David Reddy, “Around 78% of people dying from malaria are children less than 5 years of age. The timely development of age-appropriate formulations to address the needs of this particularly vulnerable population is essential. Following this positive scientific opinion from EMA, MMV, Shin Poong and other partners can work with endemic countries to pursue national approvals for Pyramax Granules and make the medicine available to children in need.”

Jei Man Ryu, CEO of Shin Poong Pharmaceutical, commented the following, “We are proud to have reached this landmark achievement with our long-standing partner Medicines for Malaria Venture. We have worked with dedication to achieve this goal and will continue to collaborate with MMV to ensure that this important life-saving medicine reaches the children for whom we developed it. Unacceptable numbers of children continue to die of malaria and this medicine will be of enormous benefit to those children suffering from either P. vivax or P. falciparum blood-stage malaria.”

For more information on this, please go to:

11 Feb 2016


Recent modelling research shows that the development of a HIV/AIDS vaccine would be a vital component to ending the disease.

The study, which focused on low- and middle-income countries, shows that adding a vaccine could significantly reduce new HIV infections and AIDS-related fatalities. One analysis example shows that with good uptake, a 70% effective vaccine could reduce new infections by 44% in the first 10 years, and by 65% in 25 years.

The data illustrate how a vaccine could significantly reduce treatment costs and potentially total HIV/AIDS response costs over time. A wide range of product characteristics would contribute to this improvement – higher efficacy, longer-lasting protection, fewer doses, lower vaccine costs and a more effective rollout.

“These new analyses underscore the powerful potential of an AIDS vaccine to help save and improve the lives of millions in a cost-effective manner,” said Mark Feinberg, President and CEO of the International AIDS Vaccine Initiative (IAVI), which conducted the study in partnership with AVAC and Avenir Health. “It is clear that we must continue to expedite development of an effective HIV vaccine alongside the critical efforts to accelerate and sustain broad and equitable access to effective antiretroviral therapy and new approaches for pre-exposure prophylaxis.”

“Adding a vaccine to a comprehensive HIV/AIDS response will hasten the end of the global epidemic and ensure that it won’t rebound,” said AVAC Executive Director Mitchell Warren. “A safe, effective and affordable AIDS vaccine is an essential complement to the existing treatment and prevention options, and this study highlights why accelerated investments are needed for both implementation of what we have and the development of what we still need.”

For more information on this please go to: